Cargando…

Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS

BACKGROUND: CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sterjovski, Jasminka, Churchill, Melissa J, Ellett, Anne, Gray, Lachlan R, Roche, Michael J, Dunfee, Rebecca L, Purcell, Damian FJ, Saksena, Nitin, Wang, Bin, Sonza, Secondo, Wesselingh, Steven L, Karlsson, Ingrid, Fenyo, Eva-Maria, Gabuzda, Dana, Cunningham, Anthony L, Gorry, Paul R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225424/
https://www.ncbi.nlm.nih.gov/pubmed/18076768
http://dx.doi.org/10.1186/1742-4690-4-89
_version_ 1782149654581870592
author Sterjovski, Jasminka
Churchill, Melissa J
Ellett, Anne
Gray, Lachlan R
Roche, Michael J
Dunfee, Rebecca L
Purcell, Damian FJ
Saksena, Nitin
Wang, Bin
Sonza, Secondo
Wesselingh, Steven L
Karlsson, Ingrid
Fenyo, Eva-Maria
Gabuzda, Dana
Cunningham, Anthony L
Gorry, Paul R
author_facet Sterjovski, Jasminka
Churchill, Melissa J
Ellett, Anne
Gray, Lachlan R
Roche, Michael J
Dunfee, Rebecca L
Purcell, Damian FJ
Saksena, Nitin
Wang, Bin
Sonza, Secondo
Wesselingh, Steven L
Karlsson, Ingrid
Fenyo, Eva-Maria
Gabuzda, Dana
Cunningham, Anthony L
Gorry, Paul R
author_sort Sterjovski, Jasminka
collection PubMed
description BACKGROUND: CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively. RESULTS: Compared to PA-R5 Envs, A-R5 Envs had enhanced fusogenicity in quantitative cell-cell fusion assays, and reduced sensitivity to inhibition by the fusion inhibitor T-20. Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. N362 was associated with enhanced fusogenicity, faster entry kinetics, and increased sensitivity of Env-pseudotyped reporter viruses to neutralization by the CD4bs-directed Env mAb IgG1b12. Mutagenesis studies showed N362 contributes to enhanced fusogenicity of most A-R5 Envs. Molecular models indicate N362 is located adjacent to the CD4 binding loop of gp120, and suggest N362 may enhance fusogenicity by promoting greater exposure of the CD4bs and/or stabilizing the CD4-bound Env structure. CONCLUSION: Enhanced fusogenicity is a phenotype of the A-R5 Envs studied, which was associated with the presence of N362, enhanced HIV-1 entry kinetics and increased CD4bs exposure in gp120. N362 contributes to fusogenicity of R5 Envs in a strain dependent manner. Our studies suggest enhanced fusogenicity of A-R5 Envs may contribute to CD4+ T-cell loss in subjects who progress to AIDS whilst harbouring R5 HIV-1 variants. N362 may contribute to this effect in some individuals.
format Text
id pubmed-2225424
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-22254242008-02-03 Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS Sterjovski, Jasminka Churchill, Melissa J Ellett, Anne Gray, Lachlan R Roche, Michael J Dunfee, Rebecca L Purcell, Damian FJ Saksena, Nitin Wang, Bin Sonza, Secondo Wesselingh, Steven L Karlsson, Ingrid Fenyo, Eva-Maria Gabuzda, Dana Cunningham, Anthony L Gorry, Paul R Retrovirology Research BACKGROUND: CCR5-restricted (R5) human immunodeficiency virus type 1 (HIV-1) variants cause CD4+ T-cell loss in the majority of individuals who progress to AIDS, but mechanisms underlying the pathogenicity of R5 strains are poorly understood. To better understand envelope glycoprotein (Env) determinants contributing to pathogenicity of R5 viruses, we characterized 37 full-length R5 Envs from cross-sectional and longitudinal R5 viruses isolated from blood of patients with asymptomatic infection or AIDS, referred to as pre-AIDS (PA) and AIDS (A) R5 Envs, respectively. RESULTS: Compared to PA-R5 Envs, A-R5 Envs had enhanced fusogenicity in quantitative cell-cell fusion assays, and reduced sensitivity to inhibition by the fusion inhibitor T-20. Sequence analysis identified the presence of Asn 362 (N362), a potential N-linked glycosylation site immediately N-terminal to CD4-binding site (CD4bs) residues in the C3 region of gp120, more frequently in A-R5 Envs than PA-R5 Envs. N362 was associated with enhanced fusogenicity, faster entry kinetics, and increased sensitivity of Env-pseudotyped reporter viruses to neutralization by the CD4bs-directed Env mAb IgG1b12. Mutagenesis studies showed N362 contributes to enhanced fusogenicity of most A-R5 Envs. Molecular models indicate N362 is located adjacent to the CD4 binding loop of gp120, and suggest N362 may enhance fusogenicity by promoting greater exposure of the CD4bs and/or stabilizing the CD4-bound Env structure. CONCLUSION: Enhanced fusogenicity is a phenotype of the A-R5 Envs studied, which was associated with the presence of N362, enhanced HIV-1 entry kinetics and increased CD4bs exposure in gp120. N362 contributes to fusogenicity of R5 Envs in a strain dependent manner. Our studies suggest enhanced fusogenicity of A-R5 Envs may contribute to CD4+ T-cell loss in subjects who progress to AIDS whilst harbouring R5 HIV-1 variants. N362 may contribute to this effect in some individuals. BioMed Central 2007-12-12 /pmc/articles/PMC2225424/ /pubmed/18076768 http://dx.doi.org/10.1186/1742-4690-4-89 Text en Copyright © 2007 Sterjovski et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Sterjovski, Jasminka
Churchill, Melissa J
Ellett, Anne
Gray, Lachlan R
Roche, Michael J
Dunfee, Rebecca L
Purcell, Damian FJ
Saksena, Nitin
Wang, Bin
Sonza, Secondo
Wesselingh, Steven L
Karlsson, Ingrid
Fenyo, Eva-Maria
Gabuzda, Dana
Cunningham, Anthony L
Gorry, Paul R
Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
title Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
title_full Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
title_fullStr Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
title_full_unstemmed Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
title_short Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS
title_sort asn 362 in gp120 contributes to enhanced fusogenicity by ccr5-restricted hiv-1 envelope glycoprotein variants from patients with aids
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2225424/
https://www.ncbi.nlm.nih.gov/pubmed/18076768
http://dx.doi.org/10.1186/1742-4690-4-89
work_keys_str_mv AT sterjovskijasminka asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT churchillmelissaj asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT ellettanne asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT graylachlanr asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT rochemichaelj asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT dunfeerebeccal asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT purcelldamianfj asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT saksenanitin asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT wangbin asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT sonzasecondo asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT wesselinghstevenl asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT karlssoningrid asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT fenyoevamaria asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT gabuzdadana asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT cunninghamanthonyl asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids
AT gorrypaulr asn362ingp120contributestoenhancedfusogenicitybyccr5restrictedhiv1envelopeglycoproteinvariantsfrompatientswithaids